Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of ...
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing Myriad Genetics, a leading molecular diagnostic testing and precision medicine company, has released new data from the MONSTAR-SCREEN-3 study demonstrating the potential of its Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers. The findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. These findings reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions. The study also found that in patients diagnosed with reselectable colorctal cancer, ctDNA detected one month after surgery was strongly associated with disease progression.
Опубликовано : 4 дня назад от Myriad Genetics, Inc. - (GLOBE NEWSWIRE) в Health Science
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MON... [6115 symbols]
